**Psychedelic knowledge and opinions in psychiatric professional conference attendees**

**Demographics**

1. Age: \_\_\_\_\_
2. Gender:
	1. Male
	2. Female
	3. Other
3. What is your current training level?
	* 1. Resident
		2. Fellow
		3. Completed residency/fellowship (attending level)
		4. Non-physician
	1. For participants selecting i or ii: What year did you complete residency training in? \_\_\_\_\_\_\_\_\_\_\_\_
4. If you are in a fellowship or have completed fellowship training, in what field have you trained?
	1. Addiction psychiatry
	2. Child psychiatry
	3. Consult-liaison psychiatry
	4. Forensic Psychiatry
	5. Geriatric psychiatry
	6. Neuropsychiatry
	7. Other\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_
5. What is your primary daily activity (choose one)?
	1. Clinical care
	2. Research
	3. Administration
	4. Other\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

**Knowledge**

1. Which of these psychedelics are not found in natural sources (select all that apply)?
2. Ibogaine
3. LSD
4. Mescaline
5. N,N-Dimethyltryptamine
6. Psilocybin
7. 5-MeO-DMT (5-methoxy-N,N-dimethyltryptamine)
8. None of the above
9. What is the prevalence of hallucinogen use disorder among those 18 years of age and older in the US?
	1. <0.1%
	2. 1%
	3. 5%
	4. 10%
	5. 35%
10. Which indigenous psychedelic from South America has led to a significant tourism industry, drawing large numbers of travelers from developed countries?
	1. Ayahuasca
	2. Ibogaine
	3. Mescaline
	4. Psilocybin
	5. 5-MeO-DMT (5-methoxy-N,N-dimethyltryptamine)
11. Classical psychedelics primarily act on the brain through which neurotransmitter system?
	1. Cannabinoid
	2. Dopamine
	3. GABA
	4. Norepinephrine
	5. Serotonin
12. Psilocybin is in which phase of clinical trials for consideration by the FDA as a treatment for Major Depressive Disorder?
	1. Not currently being investigated in such a trial
	2. Phase 1
	3. Phase 2
	4. Phase 3
	5. Phase 4
13. MDMA **(3,4-methylenedioxy-methamphetamine)** is in which phase of clinical trials for consideration by the FDA as a treatment for Posttraumatic Stress Disorder?
	1. Not currently being investigated in such a trial
	2. Phase 1
	3. Phase 2
	4. Phase 3
	5. Phase 4
14. In addition to containing a plant that has a psychedelic compound in it, Ayahuasca also includes a plant that contains which of the following type of compounds?
	1. Amphetamine
	2. Benzodiazepine
	3. Cannabinoid
	4. Monoamine oxidase inhibitor
	5. Opioid
15. Ibogaine is associated with which potentially fatal side effect?
	1. Bacterial meningitis
	2. Cardiac arrest
	3. Ischemic stroke
	4. Impairment of blood clotting
	5. Renal failure

**Opinions**

The following questions will ask about your attitudes towards psychedelic substances such as 5-MeO-DMT (5-methoxy-N,N-dimethyltryptamine); Ayahuasca; **DMT (**N,N-Dimethyltryptamine**);** LSD; **Psilocybin; and MDMA (3,4-methylenedioxy-methamphetamine).**

1. Psychedelics show promise in treating psychiatric disorders.
	1. Strongly disagree
	2. Moderately disagree
	3. Neutral
	4. Moderately agree
	5. Strongly agree
2. Psychedelics show promise in treating substance use disorders.
	1. Strongly disagree
	2. Moderately disagree
	3. Neutral
	4. Moderately agree
	5. Strongly agree
3. I am concerned about the potential legalization of psychedelic compounds for medical use.
	1. Strongly disagree
	2. Moderately disagree
	3. Neutral
	4. Moderately agree
	5. Strongly agree
4. The federal government should fund research into potential psychedelic treatments for mental health and substance use disorders.
	1. Strongly disagree
	2. Moderately disagree
	3. Neutral
	4. Moderately agree
	5. Strongly agree
5. Recreational/non-medical use of psychedelics should be legalized.
	1. Strongly disagree
	2. Moderately disagree
	3. Neutral
	4. Moderately agree
	5. Strongly agree
6. Medical use of psychedelics should be legalized.
	1. Strongly disagree
	2. Moderately disagree
	3. Neutral
	4. Moderately agree
	5. Strongly agree
7. How frequently have patients or families asked you about psychedelic-assisted therapies?
	1. Never
	2. Once
	3. A few times
	4. Often
8. What are your biggest concerns (if any) if psychedelics are legalized for medical use?
9. Addictive potential
10. Cost/Insurance coverage
11. Diversion
12. Lack of trained providers
13. Logistics of psychedelic assisted psychotherapy sessions
14. Medication interactions
15. Exploitation of patients under the influence of psychedelics
16. Time requirement for psychedelic assisted psychotherapy sessions
17. Use in patients where it should contraindicated (psychosis, etc.)
18. No concerns
19. Other\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_
20. What are you most interested in learning about in preparation for potential use of psychedelics in treatment?
	1. Addictive potential
	2. How to conduct psychedelic assisted psychotherapy
	3. Management of “bad trips”
	4. Medication interactions
	5. Patients who should be excluded from treatment with psychedelics
	6. Pharmacology of psychedelics
	7. Side effects of psychedelics
	8. Potential benefits
	9. Other\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_
21. Which information sources have you used to inform yourself about potential psychedelic treatments (select all that apply)?
	1. Academic journal articles
	2. News/magazine articles
	3. Documentary films
	4. Television
	5. Textbooks
	6. Books (non-text book)
		1. How to Change Your Mind: How to Change Your Mind: What the New Science of Psychedelics Teaches Us About Consciousness, Dying, Addiction, Depression, and Transcendence
		2. A Really Good Day: How Microdosing Made a Mega Difference in My Mood, My Marriage, and My Life
		3. Psychedelic Medicine: The Healing Powers of LSD, MDMA, Psilocybin, and Ayahuasca
		4. Other\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_
	7. Colleagues
	8. Conference presentations (excluding this one)
	9. Other\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_
	10. None
22. How many hours of formal didactics about psychedelics (on either therapeutic use or abuse/misuse) did you receive during residency training?\_\_\_\_\_\_\_\_\_\_\_\_\_
23. How many hours of formal didactics about psychedelics (on either therapeutic use or abuse/misuse) do you think you should have received during residency training?\_\_\_\_\_\_\_
24. If you have any additional thoughts or concerns regarding psychedelic therapies please feel free to share them here.